TriangleEpcoritamab (NCT06672705)
Epcoritamab trial for Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder (NCT06672705). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for adults with post transplant lymphoproliferative disorder, a lymphoma that can develop after an organ or stem cell transplant, that has come back or not responded to treatment.
The idea: epcoritamab is a bispecific antibody given as a shot under the skin. One end binds CD3 on T cells, and the other binds CD20 on B cells and some lymphoma cells, bringing immune cells to the cancer.
The study looks at safety and effectiveness.
This phase 1 study plans 26 patients. At the Ohio State University Comprehensive Cancer Center in Columbus, Timothy Voorhees leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.